Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap ...
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory ...
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Morphic is a biopharmaceutical company ...
AbbVie is ditching work on all the alpha V beta 6 (αvβ6) inhibitors that it paid $20 million to license from Morphic Therapeutic in 2020. The Big Pharma is culling the work because of a suspected ...
Explore the Morphic Holding stock price history with detailed daily historical prices, including open, high, low, close, and volume data. Review past trends, identify key price levels, and find the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results